Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
Open Access
- 11 March 2022
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (7), 1036-1043
- https://doi.org/10.1136/annrheumdis-2021-222096
Abstract
Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response. Methods Adult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination. Results ARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (pConclusions We provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX. Trial registration number NCT04754698.Funding Information
- Instituto Butantan
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/03756–4, 2018/09937-9, 2019/17272-0, 2020/09367-8)
- B3 - Bolsa de Valores do Brasil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (303379/2018-9, 304984/2020-5, 305242/2019-9, 305556/2017-7)
- Instituto Todos pela Saúde (#01/2021)
This publication has 50 references indexed in Scilit:
- Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort studyAnnals Of The Rheumatic Diseases, 2020
- 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsAnnals Of The Rheumatic Diseases, 2017
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals Of The Rheumatic Diseases, 2013
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study: Table 1.The Journal of Rheumatology, 2011
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnnals Of The Rheumatic Diseases, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- The American College of Rheumatology 1990 criteria for the classification of takayasu arteritisArthritis & Rheumatism, 1990
- The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosisArthritis & Rheumatism, 1990